Psyence Biomedical Ltd. Stock Price, News & Analysis

Psyence BioMed (NASDAQ: PBM) has announced a 1-for-7.97 reverse stock split effective May 5, 2025. The consolidation, approved by shareholders on April 16, aims to regain compliance with Nasdaq's minimum bid price requirement. Following the split, PBM's outstanding shares will decrease from 4,648,610 to 583,263. The stock will continue trading under the symbol "PBM" with a new CUSIP number 74449F308. No fractional shares will be issued - fractions less than 0.5 will be rounded down, while those 0.5 or greater will be rounded up. The consolidation affects all shareholders uniformly and won't alter percentage interests except for minor adjustments from fractional shares. Continental Stock Transfer & Trust Company serves as the exchange agent.

Psyence BioMed (NASDAQ: PBM) has received a notification from Nasdaq on April 16, 2025, indicating non-compliance with the minimum bid price requirement of $1.00 per share. The company's stock price remained below this threshold for 30 consecutive business days from March 5 through April 15, 2025.

Following a previous monitoring period granted on December 20, 2024, this notification constitutes a Staff Delisting Determination. PBM plans to appeal and request a hearing, which will temporarily stay the suspension of trading and delisting.

To address this issue, shareholders approved a reverse stock split at a Special Meeting on April 16, 2025, with the Board of Directors setting a final ratio of 1-for-7.97. While trading continues under 'PBM', there is no guarantee the company will successfully appeal or regain compliance with Nasdaq listing requirements.

Psyence BioMed (NASDAQ: PBM) has announced a USD $500,000 follow-on investment in PsyLabs, strengthening their partnership in psychedelic medicine development. This builds upon their September 2024 agreement where PBM acquired an 11.13% equity stake in PsyLabs.

The investment includes two key components:

• An exclusive, royalty-bearing IP licensing agreement for pharmaceutical-grade, EU-GMP, nature-derived psilocybin supply
• An exclusive right of first refusal for worldwide supply of pharmaceutical-grade, nature-derived Ibogaine

The partnership focuses on developing treatments for Substance Use Disorders (SUD), including Alcohol Use Disorder (AUD). PsyLabs will provide Psyence BioMed with high-quality psychedelic compounds to support their clinical pipeline and therapeutic development efforts. The deal is subject to definitive agreements and regulatory approvals.

Psyence BioMed (NASDAQ: PBM) has signed a Letter of Intent with Southern Star Research, an Australian contract research organization, to expand its Phase IIb clinical trial for psilocybin-assisted therapy. The trial focuses on treating adjustment disorder in cancer patients.

The partnership aims to accelerate the clinical trial timeline by leveraging Southern Star Research's national oncology and mental health network. Adjustment disorder, the seventh most frequently diagnosed psychiatric condition globally, currently lacks FDA-approved pharmaceutical treatments.

The company is transitioning trial management responsibilities from iNGENū CRO to Southern Star Research to ensure operational efficiency. A corporate webinar discussing the new agreement is scheduled for April 10, 2025, at 12:00 PM EST.

Psyence Biomedical (NASDAQ: PBM) provided a corporate update highlighting its progress in psychedelic medicine development. The company is conducting a Phase IIb clinical trial in Australia, focusing on adjustment disorder in cancer patients, benefiting from up to 43.5% R&D tax rebates and favorable regulatory framework.

The company has secured an exclusive IP licensing agreement with PsyLabs for EU-GMP certified psychedelic compounds, including psilocin, mescaline, ibogaine, and DMT. They've strengthened their Scientific Advisory Board with Dr. Dan Stein and Dr. Al Garcia-Romeu from Johns Hopkins.

PBM is planning a new clinical trial for Alcohol Use Disorder (AUD) and Substance Use Disorders. The company maintains a debt-free status with access to ATM financing and Equity Line of Credit (ELOC) for capital needs. A corporate webinar is scheduled for April 10, 2025, to discuss ongoing initiatives and future plans.

Psyence Biomedical (NASDAQ: PBM) has strengthened its Scientific Advisory Board with the appointment of Dr. Dan J. Stein, Professor and Chair of Psychiatry at the University of Cape Town and Director of the South African Medical Research Council Unit on Risk & Resilience in Mental Disorders.

Dr. Stein joins existing SAB members including Chair Dr. Albert Garcia-Romeu (Johns Hopkins), Dr. Seth Feuerstein (Yale), and Dr. Clive Ward-Able (Medical Director). The company is currently conducting a Phase IIb clinical trial of psilocybin for Adjustment Disorder in Palliative Care and plans to advance development for Alcohol Use Disorder.

Dr. Stein brings significant expertise in psychopharmacology, with fellowship and residency training at Columbia University. His research has earned notable recognition, including the Max Hamilton Award and Ethics in Psychopharmacology Award from the International College of Neuropsychopharmacologicum.

Psyence Biomedical (Nasdaq: PBM) has appointed Dr. Albert P. Garcia-Romeu as Chair of its newly established Scientific Advisory Board (SAB). Dr. Garcia-Romeu, currently Associate Professor at Johns Hopkins University School of Medicine and Associate Director of the Johns Hopkins Center for Psychedelic and Consciousness Research, brings extensive expertise in psilocybin research and clinical trials.

The appointment comes as the company prepares for the randomization of its first patient in the Pallicybin Phase IIb clinical trial, investigating psilocybin as a potential treatment for Adjustment Disorder in Palliative Care. The company is also advancing preparations for a second development indication in Alcohol Use Disorder.

The SAB currently includes Dr. Clive Ward Able, Medical Director of Psyence Biomedical, and Dr. Seth Feuerstein from Yale University's Department of Psychiatry, with plans to recruit additional members.

Psyence Biomed (Nasdaq: PBM) has completed a $2.0 million private placement through the sale of 1,000,000 common shares with accompanying warrants. The offering included series A common warrants and short-term series B common warrants, both with an exercise price of $2.00 per share. Series A warrants expire in five years while series B warrants expire in two years.

The transaction was facilitated by H.C. Wainwright & Co. as the exclusive placement agent. The company plans to use the net proceeds for working capital and general corporate purposes. The securities were offered under Section 4(a)(2) of the Securities Act and Regulation D, and the company has agreed to file a resale registration statement.

Psyence Biomed (Nasdaq: PBM) has announced a $2.0 million private placement through the sale of 1,000,000 common shares at $2.00 per share. The offering includes series A common warrants and short-term series B common warrants, both with an exercise price of $2.00 per share. Series A warrants expire in five years while series B warrants expire in two years.

The placement, expected to close around December 24, 2024, is being managed by H.C. Wainwright & Co. as exclusive placement agent. The company plans to use the net proceeds for working capital and general corporate purposes. The securities are being offered under Section 4(a)(2) of the Securities Act and Regulation D, and the company has agreed to file a resale registration statement.